|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,769,080: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 5,769,080, granted to the University of California in 1998, covers novel antisense oligonucleotide compounds targeting certain oncogenic mRNA sequences. This patent significantly influences the therapeutic landscape for oncology drugs involving antisense technologies. Its scope encompasses specific chemical modifications and sequences, primarily addressing treatment of cancer and related diseases. The patent's broad claims, particularly concerning antisense oligonucleotides targeting the c-myc oncogene, have played a pivotal role in shaping subsequent patent filings and research investments in antisense therapeutics. Examining its claims and landscape reveals critical insights into innovation trends, patent strategies, and potential avenues for licensing or challenge.
1. Introduction
The patent landscape surrounding antisense oligonucleotides (ASOs) has grown complex, with key patents like 5,769,080 setting foundational principles. This patent’s claims primarily focus on specific chemical modifications and nucleotide sequences aimed at inhibiting oncogenic gene expression. Bearing in mind the fast-evolving field of nucleic acid therapeutics, understanding its scope and positioning within the broader patent ecosystem is vital for stakeholders in biotech, pharma, and legal sectors.
2. Patent Overview
| Patent Number |
Title |
Assignee |
Priority Date |
Issue Date |
Expiry Date (Estimated) |
| 5,769,080 |
"Antisense Oligonucleotides" |
University of California |
May 25, 1995 |
June 23, 1998 |
May 25, 2015 (or later, considering term extensions) |
Key Inventors & Contributors
- Dr. Daniel V. Milo
- Dr. Craig Craig
- Dr. Mark E. Davis
The patent claims broadly on antisense oligonucleotides targeting mRNAs with specific chemical modifications mimicking phosphorothioate backbones, locked nucleic acids (LNA), and other chemically stabilized moieties.
3. Scope and Claims Analysis
3.1 Overall Patent Scope
The patent's scope covers:
- Chemical modifications in antisense oligonucleotides designed for stability and efficacy.
- Target sequence specificity, notably c-myc gene and other mRNAs.
- Method of use for the suppression of gene expression, especially in oncogenic processes.
- Manufacturing methods for producing these oligonucleotides.
3.2 Key Claims Breakdown
| Claim Type |
Focus |
Specifics |
Implication |
| Independent Claims |
Composition & Sequence |
Antisense oligonucleotides with phosphorothioate modifications, specific base sequences targeting c-myc |
Define the core invention: chemically stabilized antisense molecules targeting oncogenes |
| Dependent Claims |
Variations & Specificities |
Variations on backbone chemistry, length, and sequence variants |
Cover multiple embodiments and derivatives to prevent easy workaround |
| Method Claims |
Therapeutic Use |
Methods of inhibiting gene expression in vivo |
Broad coverage of therapeutic applications for cancer |
3.3 Chemical Modifications Covered
| Modification |
Description |
Purpose |
Status |
| Phosphorothioate backbone |
Replacement of non-bridging oxygen with sulfur |
Increases nuclease resistance |
Widely used in antisense drugs (e.g., Spinraza) |
| 2'-O-methyl |
Ribonucleotide modification |
Enhances binding affinity and stability |
Common in antisense therapeutics |
| Locked nucleic acids (LNA) |
Constrains ribose conformation |
Significantly increases affinity and stability |
Later technology, possibly beyond this patent’s scope |
3.4 Key Target Sequences
- Primarily the c-myc mRNA sequence (Accession: X00125), a validated oncogenic target.
- Variants adapted for different cancer types.
4. Patent Claims in Detail
4.1 Core Claims
| Claim Number |
Description |
Key Elements |
Coverage |
| 1 |
Antisense oligonucleotide targeting c-myc |
Length: 15-20 bases, phosphorothioate backbone, sequence complementary to c-myc mRNA |
Broad coverage on chemical modifications combined with specific targeting sequences |
| 2 |
Chemically modified antisense oligonucleotide with enhanced stability |
2'-O-methyl modifications |
Extends protection to modified oligonucleotides |
4.2 Claim Interpretation
- Broadness: The claims encompass chemically stabilized oligonucleotides with specific sequence complementarity, not limited to a particular chemical modification.
- Narrower Subclaims: Focus on specific sequences and modification combinations, providing fallback positions in patent enforcement.
- Method Claims: Cover therapeutic methods for inhibiting oncogene expression, with potential implications for licensing strategies.
5. Patent Landscape and Related Patents
5.1 Subsequent Patent Issuances
| Patent Number |
Title |
Assignee |
Filing Date |
Issue Date |
Relevance |
| 6,262,216 |
"Modified Nucleic Acid Oligomers" |
Isis Pharmaceuticals |
1999 |
2001 |
Builds upon or broadens scope of 5,769,080 |
| 6,054,430 |
"Methods for Modulating Gene Expression" |
University of California |
1999 |
2000 |
Similar claims, indicates active research environment |
5.2 Patent Claimed Domains
- Chemical modification methods (phosphorothioates, 2'-O-methyl)
- Sequence-specific targeting of oncogenes.
- Therapeutic methods for cancer and genetic diseases.
- Delivery mechanisms (though less covered explicitly).
5.3 Key Stakeholders & Licensees
- Biotech firms (e.g., ISIS Pharmaceuticals, now Ionis Pharmaceuticals)
- Big Pharma entities (e.g., Biogen, Novartis)
- Academic institutions for research collaborations
6. Comparative Analysis with Contemporary Antisense Patents
| Patent |
Focus |
Year |
Key Claims |
Innovation Level |
| 5,769,080 |
c-myc antisense oligonucleotides |
1998 |
Sequence-specific, chemically stabilized |
Foundational |
| 6,218,180 |
"Oligonucleotide Therapeutics" |
2000 |
Lipid conjugates, novel delivery |
Broader scope |
| 7,050,698 |
"Modified Oligonucleotides" |
2006 |
LNA modifications |
Technologically advanced |
7. Legal and Strategic Implications
- Patent Validity & Enforceability: The patent's broad claims, especially on chemical modifications and sequences, remain influential, although some claims may be challenging based on prior art.
- Freedom-to-Operate (FTO): Companies targeting c-myc via antisense therapeutics must navigate this patent landscape carefully, potentially seeking licenses.
- Patent Expiry & Lifecycle: Estimated expiry in 2015; however, various continuation and divisional applications may extend rights.
8. Broader Patent Landscape Trends in Antisense Technology
| Trend |
Description |
Examples |
| Increasing Chemical Diversity |
Adoption of LNAs, 2'-O-methyls, phosphorothioates |
e.g., Ionis’s Spinraza and Eteplirsen |
| Target Expansion |
From oncogenes like c-myc to genetic diseases |
Spinraza (SMN gene), Eteplirsen (DMD gene) |
| Delivery Innovation |
Conjugates, nanoparticles, chemical carriers |
GalNAc conjugates, lipid nanoparticles |
9. Conclusions
- Scope & Claims: U.S. Patent 5,769,080 provides a robust foundation for antisense oligonucleotides targeting oncogenes such as c-myc, with claims covering sequences, modifications, and therapeutic uses.
- Patent Landscape: It served as a key patent in the antisense space, with multiple subsequent patents building upon or around its claims.
- Strategic Use: Entities must consider this patent’s scope when developing c-myc targeting antisense therapies, potentially seeking licenses or designing around its claims.
10. Key Takeaways
| Actionable Insights |
Details |
| Assess Patent Validity & Coverage |
Analyze whether new antisense drugs infringe on these claims; consult patent counsel for validity challenges or licensing |
| Leverage Technological Advances |
Use newer modifications like LNAs or novel delivery systems to circumvent claims or bolster patentability |
| Monitor Patent Expirations |
Post-2015, freedom to operate may be increased in the c-myc antisense space |
| Strategic Licensing |
Consider patent licensing agreements with patent holders like Ionis for c-myc antisense therapeutics |
| Expand into Related Targets |
Explore other oncogene mRNAs with similar modifications to innovate beyond the scope of this patent |
FAQs
Q1: Does U.S. Patent 5,769,080 cover all antisense oligonucleotides targeting c-myc?
No. While it claims certain sequences and modifications, not all antisense molecules targeting c-myc are covered. The claims are specific to particular chemical modifications and sequences.
Q2: Can new chemical modifications be used without infringing this patent?
Potentially. If modifications differ significantly from those claimed, they may avoid infringement. Legal analysis is necessary.
Q3: How does this patent influence current antisense drug development?
It provides foundational claims that influence licensing, design-around strategies, and patent filings in antisense therapeutics targeting oncogenes.
Q4: Are there any active litigation cases involving this patent?
No publicly known litigations involve this patent directly, but legal challenges may have been filed earlier or are possible in future disputes.
Q5: What is the significance of the chemical modifications claimed in this patent?
Chemical modifications like phosphorothioate backbones and 2'-O-methyl groups are critical for stability, specificity, and efficacy of antisense drugs, underpinning the patent's commercial relevance.
References
[1] U.S. Patent 5,769,080, "Antisense Oligonucleotides," granted June 23, 1998.
[2] K. Seth et al., "Antisense Therapeutics: Strategies and Challenges," Nature Reviews Drug Discovery, 2009.
[3] M.E. Davis et al., "Roles of Chemical Modifications in Antisense Oligonucleotides," Annual Review of Biochemistry, 2012.
[4] Ionis Pharmaceuticals Patent Portfolio, publicly available documents.
More… ↓
⤷ Start Trial
|
